Beyond the Chest X-ray: How Nuclear Imaging Reveals the Hidden Burden of Sarcoidosis

Gallium Scintigraphy, FDG PET/CT, and the Future of Precision Imaging in Systemic Granulomatous Disease

Category: Nuclear Medicine | Molecular Imaging | Thoracic Radiology | PET/CT | Inflammatory Disease

Keywords: Sarcoidosis, FDG PET/CT, Gallium Scan, Panda Sign, Lambda Sign, Nuclear Medicine, Granulomatous Disease, Molecular Imaging, Chest CT, Whole-Body Imaging

Executive Summary

Sarcoidosis is one of the most fascinating and challenging multisystem inflammatory diseases encountered in modern medicine.

Although pulmonary involvement remains the hallmark of the disease, sarcoidosis is fundamentally a systemic granulomatous disorder capable of affecting virtually every organ, including the lymph nodes, skin, eyes, heart, liver, spleen, nervous system, and musculoskeletal system. The remarkable diversity of clinical manifestations frequently delays diagnosis and often leads clinicians through an extensive differential diagnostic workup.

While conventional chest radiography and high-resolution CT remain essential imaging tools, they primarily depict structural abnormalities. Nuclear medicine, by contrast, provides a completely different perspective—one that visualizes active inflammation before irreversible structural damage occurs.

This case highlights how characteristic uptake patterns on Gallium-67 scintigraphy and FDG PET/CT can reveal the systemic nature of sarcoidosis, guide biopsy, assess disease extent, evaluate prognosis, and monitor treatment response. Rather than simply identifying anatomical abnormalities, molecular imaging uncovers the biological activity of granulomatous inflammation throughout the body.

A Patient Whose Symptoms Refused to Fit a Single Diagnosis

Imagine a patient presenting with a persistent dry cough, progressive fatigue, intermittent fever, weight loss, and enlarged mediastinal lymph nodes.

A chest radiograph may suggest bilateral hilar lymphadenopathy.

Chest CT may demonstrate symmetrical mediastinal lymph node enlargement and scattered pulmonary nodules.

Laboratory testing may reveal elevated serum angiotensin-converting enzyme (ACE) levels.

Yet none of these findings alone establishes the diagnosis.

The differential diagnosis remains broad and includes:

Tuberculosis
Lymphoma
Metastatic malignancy
Fungal infection
Occupational granulomatous disease
Drug-induced granulomatous reactions
Sarcoidosis

The challenge is not merely identifying enlarged lymph nodes—it is determining why they are enlarged.

This is where molecular imaging fundamentally changes the diagnostic pathway.

The First Nuclear Medicine Clue

The initial nuclear imaging study in this case was Gallium-67 scintigraphy.

Unlike conventional anatomical imaging, Gallium accumulates preferentially within areas of active granulomatous inflammation.

The scan demonstrated increased tracer uptake involving:

Nasal region
Lacrimal glands
Parotid glands
Mediastinal lymph nodes
Pulmonary parenchyma
Liver
Spleen
Subcutaneous nodules
Epitrochlear lymph nodes

This highly characteristic distribution strongly supports the diagnosis of systemic sarcoidosis rather than infection or metastatic disease.

Figure 1. Gallium-67 Scintigraphy Demonstrating the Classic Panda and Lambda Signs in Systemic Sarcoidosis

Whole-body Gallium-67 scintigraphy demonstrates increased tracer uptake involving the lacrimal glands, parotid glands, mediastinal lymph nodes, lungs, liver, spleen, and peripheral lymph nodes. The characteristic Panda and Lambda signs strongly support the diagnosis of active systemic sarcoidosis.

Radiology Impression

Symmetric bilateral hilar uptake.
Bilateral parotid and lacrimal gland uptake.
Multiorgan inflammatory involvement.
Findings highly suggestive of systemic sarcoidosis.

Recognizing the Classic "Panda Sign"

Among the most memorable imaging findings in nuclear medicine is the Panda Sign.

The name originates from the symmetrical accumulation of Gallium within the lacrimal glands, parotid glands, and salivary glands.

When viewed on anterior scintigraphic images, these areas of tracer uptake resemble the facial markings of a giant panda.

Although not entirely specific for sarcoidosis, the Panda Sign remains one of the classic imaging patterns associated with active systemic granulomatous inflammation.

Recognizing this sign allows radiologists and nuclear medicine physicians to narrow an otherwise extensive differential diagnosis significantly.

The Equally Important "Lambda Sign"

Another hallmark of Gallium scintigraphy is the Lambda Sign.

This pattern represents symmetrical tracer uptake within:

Right hilar lymph nodes
Left hilar lymph nodes
Right paratracheal lymph nodes

Together, these three foci create an appearance resembling the Greek letter λ (lambda).

Historically, the combined presence of the Panda Sign and Lambda Sign has been considered highly suggestive of sarcoidosis in the appropriate clinical setting.

Although FDG PET/CT has largely replaced Gallium scintigraphy in many institutions, these classic signs remain important educational landmarks in nuclear medicine.

Why Molecular Imaging Matters

Chest CT demonstrates anatomy.

PET demonstrates biology.

This distinction is critical.

Granulomas become metabolically active long before they produce irreversible structural damage.

Activated macrophages and T lymphocytes consume increased amounts of glucose, producing intense FDG accumulation on PET imaging.

Consequently, PET identifies inflammatory activity rather than simply depicting residual fibrotic scars.

This biological information frequently alters patient management by distinguishing active inflammation from chronic inactive disease.

Clinical Pearl

Sarcoidosis is rarely diagnosed because of a single imaging finding.

Instead, the diagnosis emerges from the integration of:

Clinical presentation
Laboratory abnormalities
Cross-sectional imaging
Nuclear medicine findings
Histopathological confirmation of non-caseating granulomas

Among these components, molecular imaging uniquely demonstrates the functional activity of disease throughout the entire body, allowing clinicians to identify occult organ involvement that may otherwise remain undetected.

Teaching Point

Whenever bilateral hilar lymphadenopathy is accompanied by unexplained systemic symptoms, radiologists should think beyond structural imaging.

Whole-body molecular imaging can reveal clinically silent extrapulmonary disease, identify the most appropriate biopsy site, estimate total inflammatory burden, and provide an objective baseline for monitoring response to immunosuppressive therapy.

In sarcoidosis, the question is no longer "Where are the enlarged lymph nodes?"

The more important question becomes:

"Which granulomas are still biologically active?"

FDG PET/CT: From Anatomical Imaging to Functional Disease Mapping

While Gallium-67 scintigraphy established the foundation of nuclear imaging in sarcoidosis, ^18F-fluorodeoxyglucose (FDG) PET/CT has become the preferred molecular imaging modality in many tertiary referral centers.

The transition from Gallium imaging to FDG PET/CT represents more than a technological improvement—it reflects a shift from qualitative observation to quantitative assessment of inflammatory activity.

Unlike conventional imaging, FDG PET/CT evaluates metabolic activity, allowing physicians to identify active granulomatous inflammation throughout the body before irreversible organ damage develops.

Figure 2. Whole-Body FDG PET/CT Demonstrating Multiorgan Granulomatous Inflammation

Whole-body FDG PET/CT demonstrates intense hypermetabolic activity involving mediastinal lymph nodes and multiple extrapulmonary organs, reflecting active granulomatous inflammation. PET/CT is valuable for disease staging, biopsy guidance, treatment monitoring, and prognostic assessment in systemic sarcoidosis.

Radiology Impression

Hypermetabolic mediastinal lymphadenopathy.
Active systemic inflammatory disease.
No imaging evidence of metastatic malignancy.
Imaging findings are compatible with active sarcoidosis.

Why FDG Accumulates in Sarcoidosis

The hallmark pathological feature of sarcoidosis is the formation of non-caseating granulomas.

These granulomas are composed primarily of activated macrophages, epithelioid histiocytes, multinucleated giant cells, and CD4-positive T lymphocytes.

During active inflammation, these immune cells dramatically increase glucose metabolism.

FDG, a radioactive glucose analogue, is transported into activated inflammatory cells through glucose transporters and becomes trapped intracellularly after phosphorylation.

As a result, areas of active granulomatous inflammation appear as intensely hypermetabolic foci on PET imaging.

Unlike CT, which demonstrates structural consequences of disease, PET reveals ongoing immunological activity.

Whole-Body Imaging Changes Clinical Management

One of the greatest strengths of FDG PET/CT is its ability to evaluate the entire body in a single examination.

Sarcoidosis is fundamentally a systemic disease.

Although pulmonary involvement is present in the vast majority of patients, clinically silent extrapulmonary disease is common and may significantly alter treatment decisions.

Whole-body PET/CT can identify active inflammatory lesions involving:

Mediastinal lymph nodes
Pulmonary parenchyma
Liver
Spleen
Bone marrow
Peripheral lymph nodes
Skeletal muscles
Skin
Heart
Central nervous system

Many of these lesions remain unsuspected on routine clinical examination.

Consequently, PET frequently changes both disease staging and therapeutic strategy.

Guiding the Ideal Biopsy Site

Histopathological confirmation remains the cornerstone of sarcoidosis diagnosis.

Demonstration of non-caseating granulomas, together with compatible clinical and imaging findings and exclusion of alternative causes, is required in most patients.

The challenge is determining where to obtain tissue.

FDG PET/CT provides a practical solution.

Instead of sampling the most accessible lesion, clinicians can target the most metabolically active and safely accessible lesion, thereby increasing diagnostic yield while minimizing procedural risk.

This approach is particularly valuable when thoracic lymph node biopsy would otherwise require invasive mediastinoscopy.

Assessing Disease Burden

Sarcoidosis varies enormously between patients.

Some individuals have isolated thoracic disease with spontaneous remission.

Others develop widespread multisystem inflammation involving multiple organs.

PET/CT enables physicians to quantify total inflammatory burden by evaluating:

Number of metabolically active lesions
Distribution of organ involvement
Intensity of FDG uptake
Extent of active granulomatous inflammation

This information provides a more comprehensive assessment than anatomical imaging alone and helps identify patients at increased risk for progressive disease.

Monitoring Treatment Response

Perhaps the greatest advantage of FDG PET/CT lies in longitudinal follow-up.

Clinical symptoms often improve before inflammatory activity has completely resolved.

Conversely, some patients appear clinically stable while persistent metabolic activity predicts future relapse.

Serial PET examinations allow physicians to monitor:

Reduction in inflammatory activity after corticosteroid therapy
Response to immunosuppressive agents
Residual metabolically active granulomas
Early disease recurrence

Studies have demonstrated that persistent FDG uptake following treatment is associated with an increased likelihood of subsequent relapse, even among patients who appear to have achieved clinical remission.

Differential Diagnosis: Why Sarcoidosis Is Called "The Great Mimicker"

Few inflammatory disorders imitate as many diseases as sarcoidosis.

Its imaging appearance overlaps with a broad spectrum of infectious, inflammatory, and malignant conditions.

Major differential considerations include:

Tuberculosis

Both diseases produce granulomatous inflammation.

However, tuberculosis typically demonstrates caseating granulomas, asymmetric lymphadenopathy, cavitary pulmonary lesions, and microbiological evidence of infection.

Clinical history, microbiological testing, and tissue pathology remain essential for differentiation.

Lymphoma

FDG-avid mediastinal lymphadenopathy may strongly resemble lymphoma.

Nevertheless, sarcoidosis usually demonstrates more symmetrical nodal involvement, while histopathology distinguishes reactive granulomas from malignant lymphoid proliferation.

Metastatic Malignancy

Diffuse FDG uptake within multiple lymph node stations may raise concern for metastatic cancer.

Correlation with clinical history, CT morphology, biopsy findings, and organ distribution is critical.

Fungal Infections

Systemic fungal infections such as histoplasmosis may produce granulomatous disease that closely resembles sarcoidosis on both CT and PET imaging.

Geographic exposure and microbiological studies assist in establishing the correct diagnosis.

Occupational and Environmental Granulomatous Disorders

Chronic exposure to inorganic dusts, beryllium, or environmental antigens may generate granulomatous reactions that are clinically and radiologically indistinguishable from sarcoidosis.

Occupational history, therefore, remains an indispensable component of patient evaluation.

Imaging Pearl

FDG uptake alone is not disease-specific.

PET identifies metabolic activity, not disease identity.

The diagnosis of sarcoidosis should never be based solely on increased FDG accumulation.

Instead, PET findings must always be interpreted alongside:

Clinical presentation
High-resolution CT findings
Laboratory investigations
Histopathological confirmation
Careful exclusion of infectious and malignant diseases

This integrated diagnostic approach remains the foundation of evidence-based sarcoidosis management.

Expert Insight

Modern molecular imaging has fundamentally transformed the evaluation of sarcoidosis.

The role of PET/CT is no longer limited to detecting inflammation.

Today it serves as a comprehensive platform for diagnosis, biopsy planning, disease staging, prognostic assessment, therapeutic monitoring, and personalized patient management.

Rather than replacing conventional imaging, FDG PET/CT complements radiography and high-resolution CT by adding a dimension that anatomy alone cannot provide—the visualization of living inflammatory biology.

Multisystem Manifestations: When Sarcoidosis Extends Beyond the Lungs

Although pulmonary disease dominates clinical attention, sarcoidosis should never be regarded as a lung-limited disorder.

Instead, it is a systemic immune-mediated granulomatous disease capable of involving virtually any organ. Approximately 90% of patients demonstrate thoracic involvement, yet clinically significant extrapulmonary disease is increasingly recognized as a major determinant of long-term morbidity and mortality.

For radiologists, appreciating this multisystem nature is essential because imaging often provides the first evidence of occult organ involvement before symptoms develop.

Pulmonary Sarcoidosis: The Most Common Presentation

The lungs remain the principal site of disease.

Chest radiography frequently demonstrates bilateral hilar lymphadenopathy, often accompanied by right paratracheal lymph node enlargement.

High-resolution CT (HRCT) further characterizes pulmonary involvement by revealing:

Perilymphatic micronodules
Upper-lobe predominance
Peribronchovascular nodules
Interlobular septal thickening
Fibrotic architectural distortion in advanced disease

These imaging findings reflect the characteristic lymphatic distribution of non-caseating granulomas.

Despite these classic appearances, CT alone cannot determine whether inflammatory lesions remain biologically active—a limitation addressed by FDG PET/CT.

Cardiac Sarcoidosis: The Silent Threat

Among all extrapulmonary manifestations, cardiac sarcoidosis deserves particular attention.

Although clinically recognized in only a minority of patients, autopsy studies suggest substantially higher rates of myocardial involvement.

Granulomatous inflammation within the myocardium may produce:

Conduction abnormalities
Ventricular arrhythmias
Heart block
Heart failure
Sudden cardiac death

Because structural abnormalities may initially be subtle, cardiac MRI and FDG PET/CT have become complementary imaging modalities.

Cardiac MRI excels at identifying myocardial fibrosis through late gadolinium enhancement.

FDG PET, by contrast, detects active myocardial inflammation before irreversible fibrosis develops.

This distinction has important therapeutic implications because active inflammatory disease may respond to immunosuppressive therapy.

Neurosarcoidosis: A Diagnostic Challenge

Central nervous system involvement occurs far less frequently but remains one of the most difficult manifestations to diagnose.

Patients may present with:

Cranial neuropathies
Chronic headaches
Seizures
Cognitive impairment
Pituitary dysfunction
Meningeal inflammation

MRI remains the primary imaging modality for evaluating neurosarcoidosis.

However, whole-body FDG PET/CT frequently identifies extracranial biopsy sites, allowing histological confirmation without the need for invasive neurosurgical procedures.

In this setting, PET contributes not by replacing MRI, but by facilitating diagnosis through safer tissue sampling.

Hepatic and Splenic Involvement

Granulomatous infiltration of the liver and spleen is considerably more common than clinical symptoms suggest.

Many patients remain completely asymptomatic despite extensive organ involvement.

CT findings may be subtle or even absent.

FDG PET/CT, however, often demonstrates diffuse or multifocal metabolic activity within these organs, revealing inflammatory disease before structural abnormalities become apparent.

Recognition of hepatic and splenic involvement also strengthens diagnostic confidence by demonstrating the systemic distribution typical of sarcoidosis.

Musculoskeletal Sarcoidosis

Osseous and muscular sarcoidosis represent uncommon but clinically important manifestations.

Patients may experience:

Chronic musculoskeletal pain
Myopathy
Bone lesions
Joint swelling

MRI effectively evaluates muscle edema and marrow abnormalities, whereas FDG PET/CT identifies metabolically active inflammatory lesions throughout the musculoskeletal system.

Whole-body imaging is particularly valuable because skeletal involvement is frequently multifocal and clinically unsuspected.

Ocular Sarcoidosis

The eyes are among the most frequently affected extrapulmonary organs.

Uveitis represents the classic ophthalmologic manifestation and may lead to irreversible vision loss if diagnosis is delayed.

Although ocular inflammation is primarily evaluated clinically, whole-body imaging often demonstrates simultaneous systemic disease, reinforcing the diagnosis and guiding systemic therapy.

Laboratory Biomarkers: Helpful but Imperfect

Several laboratory abnormalities support the diagnosis of sarcoidosis, although none are sufficiently sensitive or specific to establish the diagnosis independently.

Common findings include:

Elevated serum angiotensin-converting enzyme (ACE)
Hypercalcemia
Hypercalciuria
Elevated inflammatory markers

Serum ACE has historically attracted considerable attention because granuloma-associated macrophages produce increased amounts of the enzyme.

However, reported diagnostic sensitivity varies widely, limiting its utility as a stand-alone biomarker. Normal ACE levels do not exclude active sarcoidosis, and elevated levels may occur in several other conditions.

Consequently, laboratory findings should always be interpreted within the broader clinical and imaging context.

Integrating Imaging and Pathology

Despite remarkable advances in molecular imaging, histopathological confirmation remains the diagnostic reference standard.

The diagnosis of sarcoidosis rests upon three fundamental pillars:

A compatible clinical presentation.
Histological demonstration of non-caseating granulomas.
Careful exclusion of alternative granulomatous diseases, particularly tuberculosis, fungal infections, lymphoma, and other inflammatory disorders.

Imaging cannot replace tissue diagnosis.

Instead, it serves as the roadmap that directs clinicians toward the most informative biopsy site while simultaneously defining the full extent of systemic disease.

Clinical Pearl

One of the greatest misconceptions surrounding sarcoidosis is that it is primarily a pulmonary disorder.

In reality, it is a whole-body inflammatory disease.

Every imaging examination should therefore extend beyond identifying pulmonary abnormalities to actively searching for clinically silent extrapulmonary involvement.

Failure to recognize systemic disease may underestimate disease severity, delay appropriate immunosuppressive therapy, and ultimately influence patient prognosis.

Expert Perspective

The evolution of sarcoidosis imaging reflects a broader transformation occurring throughout radiology.

Traditional imaging answered the question:

"Where is the abnormality?"

Modern molecular imaging asks a more meaningful question:

"Which abnormalities remain biologically active, which organs are truly involved, and how should this information change patient management?"

This shift from anatomical observation to functional characterization represents one of the most significant advances in contemporary inflammatory imaging and underscores the central role of FDG PET/CT in precision medicine for sarcoidosis.

Future Perspectives: Precision Imaging and Artificial Intelligence in Sarcoidosis

The future of sarcoidosis imaging extends far beyond detecting inflammatory lesions.

Modern molecular imaging is rapidly evolving into a precision medicine platform capable of integrating anatomical, metabolic, immunological, and genetic information into a single patient-specific assessment.

Rather than asking whether sarcoidosis is present, future imaging will increasingly answer more sophisticated clinical questions:

Is the disease currently active?
Which organs are at greatest risk of permanent damage?
Which patient is most likely to relapse?
Which immunosuppressive therapy will provide the greatest benefit?
When can treatment safely be discontinued?

These questions represent the next frontier of imaging-guided personalized medicine.

Beyond FDG: The Next Generation of Molecular Tracers

Although FDG PET/CT remains the clinical standard for evaluating inflammatory activity, FDG is not disease-specific.

Activated inflammatory cells, malignant tumors, and infectious lesions all demonstrate increased glucose metabolism.

Consequently, investigators are actively developing more specific radiopharmaceuticals capable of directly targeting immune-cell populations involved in granulomatous inflammation.

Potential future PET tracers include:

Somatostatin receptor-targeted agents
CXCR4-directed radiopharmaceuticals
Fibroblast activation protein inhibitors (FAPI)
Macrophage-specific tracers
T-cell receptor imaging probes

These novel tracers may improve diagnostic specificity while distinguishing active immune-mediated inflammation from infection or malignancy.

As molecular imaging becomes increasingly disease-specific, personalized therapeutic decision-making will continue to improve.

PET/MRI: Combining Metabolism with Superior Soft-Tissue Contrast

Hybrid PET/MRI represents another important advance.

While PET provides metabolic information, MRI contributes exceptional soft-tissue contrast and functional tissue characterization without additional ionizing radiation.

This combination is particularly attractive for evaluating:

Cardiac sarcoidosis
Neurosarcoidosis
Pediatric patients
Musculoskeletal involvement
Long-term disease surveillance

For example, cardiac MRI identifies myocardial fibrosis through late gadolinium enhancement, whereas PET simultaneously demonstrates active myocardial inflammation.

Together, these complementary datasets distinguish irreversible scar formation from potentially reversible inflammatory disease.

This integrated assessment may directly influence immunosuppressive treatment strategies.

Artificial Intelligence and Quantitative Disease Assessment

Artificial intelligence (AI) is expected to transform the interpretation of inflammatory imaging.

Rather than simply detecting abnormal uptake, AI algorithms may automatically quantify:

Total inflammatory volume
Whole-body granuloma burden
Organ-specific metabolic activity
Longitudinal response to therapy
Probability of future relapse

Machine learning models trained on large multicenter datasets could identify imaging patterns invisible to the human observer, enabling earlier diagnosis and more accurate prognostic stratification.

Importantly, AI should function as a clinical decision-support system rather than an autonomous diagnostic tool.

Expert physician oversight remains essential for integrating imaging findings with clinical history, pathology, laboratory data, and therapeutic considerations.

Radiomics: Unlocking Hidden Imaging Biomarkers

Radiomics represents another promising area of research.

Instead of relying solely on visual interpretation, radiomics extracts hundreds of quantitative imaging features describing the lesion:

Shape
Texture
Signal heterogeneity
Spatial distribution
Metabolic complexity

These imaging biomarkers may correlate with:

Disease activity
Treatment response
Fibrotic progression
Relapse risk
Overall prognosis

Although still primarily investigational, radiomics may eventually complement conventional image interpretation by providing objective quantitative biomarkers for individualized patient care.

Precision Medicine in Sarcoidosis

Sarcoidosis is remarkably heterogeneous.

Some patients experience spontaneous remission.

Others require prolonged corticosteroid therapy.

A smaller subgroup develops progressive multiorgan disease associated with irreversible organ dysfunction.

Future precision medicine strategies will integrate:

Clinical phenotype
High-resolution CT findings
FDG PET metabolic activity
Cardiac MRI
Histopathology
Laboratory biomarkers
Genetic susceptibility
Artificial intelligence-derived imaging metrics

The goal is not simply to diagnose sarcoidosis but to predict its biological behavior in each individual patient.

Practical Reporting Tips for Radiologists

When interpreting FDG PET/CT in patients with suspected sarcoidosis, a structured reporting approach improves both diagnostic accuracy and communication.

A comprehensive report should include:

Distribution of Disease

Describe thoracic and extrapulmonary organ involvement.

Specify lymph node stations and affected organs.

Metabolic Activity

Comment on the intensity and distribution of FDG uptake.

Identify the dominant metabolically active lesions.

Biopsy Recommendation

Whenever possible, recommend the safest and most metabolically active lesion suitable for tissue sampling.

Potential Cardiac Involvement

Carefully evaluate myocardial uptake patterns after appropriate patient preparation.

Suspicious findings should prompt further assessment with dedicated cardiac imaging.

Comparison with Previous Studies

Assess interval metabolic response.

Document improvement, stability, progression, or new sites of disease.

This standardized approach increases the clinical value of molecular imaging reports while facilitating multidisciplinary patient management.

Clinical Pearls

✓ Sarcoidosis is fundamentally a systemic inflammatory disease, not simply a pulmonary disorder.

✓ FDG PET/CT identifies active inflammation, whereas CT primarily demonstrates structural abnormalities.

✓ Whole-body imaging frequently detects clinically silent extrapulmonary disease.

✓ PET-guided biopsy improves diagnostic yield by identifying the most metabolically active lesion.

✓ Persistent FDG uptake after treatment may predict future relapse despite apparent clinical remission.

Key Take-Home Messages

Sarcoidosis remains one of the most complex multisystem inflammatory diseases encountered in radiology.
Gallium scintigraphy introduced functional imaging concepts through the classic Panda Sign and Lambda Sign, while FDG PET/CT has become the modern reference standard for assessing inflammatory activity.
Molecular imaging complements conventional radiography and CT by revealing disease biology rather than anatomy alone.
Whole-body PET/CT plays a central role in diagnosis, biopsy guidance, disease staging, treatment monitoring, and prognostic evaluation.
Emerging technologies—including PET/MRI, novel immune-targeted radiotracers, radiomics, and artificial intelligence—are expected to further improve diagnostic precision and enable personalized management strategies.

Conclusion

Sarcoidosis exemplifies the transition of medical imaging from structural diagnosis to biological characterization.

Conventional imaging remains indispensable for identifying anatomical abnormalities, yet it is molecular imaging that reveals the true extent and activity of systemic granulomatous inflammation.

FDG PET/CT has transformed clinical practice by allowing physicians to visualize active disease throughout the entire body, guide histological confirmation, monitor therapeutic response, and identify patients at increased risk for relapse.

As imaging technologies continue to evolve, the integration of hybrid imaging, quantitative biomarkers, and artificial intelligence will further enhance our ability to characterize disease activity with unprecedented precision.

Ultimately, the future of sarcoidosis imaging will not be defined solely by sharper images, but by deeper biological understanding—bringing radiology closer to the goal of truly personalized, patient-centered medicine.

Frequently Asked Questions (FAQ)

1. What is sarcoidosis?

Sarcoidosis is a systemic inflammatory disease characterized by the formation of non-caseating granulomas in multiple organs. Although the lungs and intrathoracic lymph nodes are most commonly involved, virtually any organ—including the heart, liver, spleen, skin, eyes, nervous system, and musculoskeletal system—may be affected. The exact cause remains unknown, but current evidence suggests that sarcoidosis results from an abnormal immune response occurring in genetically susceptible individuals after exposure to unidentified environmental or infectious triggers.

2. Why is sarcoidosis called "The Great Mimicker"?

Few diseases imitate as many clinical and imaging conditions as sarcoidosis.

Patients may initially be suspected of having:

Tuberculosis
Lymphoma
Metastatic malignancy
Fungal infection
Autoimmune disease
Occupational granulomatous disorders

Because no single imaging finding or laboratory test is pathognomonic, diagnosis requires careful integration of clinical history, imaging, pathology, and exclusion of competing diagnoses.

3. What is the role of FDG PET/CT?

FDG PET/CT has become one of the most valuable imaging modalities for evaluating systemic sarcoidosis.

Its major clinical applications include:

Detecting occult extrapulmonary disease
Measuring total inflammatory burden
Identifying the optimal biopsy site
Assessing disease activity
Monitoring response to immunosuppressive therapy
Detecting early relapse

Unlike CT, which primarily demonstrates structural abnormalities, PET visualizes ongoing inflammatory metabolism, making it particularly useful for evaluating active disease.

4. Is Gallium scintigraphy still useful?

Yes.

Although FDG PET/CT has replaced Gallium imaging in many institutions because of superior image quality and shorter examination times, Gallium-67 scintigraphy remains historically important and continues to be used in selected clinical settings.

The classic Panda Sign and Lambda Sign remain valuable educational imaging patterns and continue to appear in board examinations and radiology teaching materials.

5. Can PET/CT diagnose sarcoidosis by itself?

No.

PET/CT demonstrates metabolic activity, not disease specificity.

Increased FDG uptake may also occur in:

Tuberculosis
Fungal infections
Lymphoma
Metastatic cancer
Other inflammatory disorders

Therefore, PET findings must always be interpreted together with clinical evaluation, laboratory testing, conventional imaging, and histopathological confirmation of non-caseating granulomas.

6. Which imaging modality is considered the reference standard?

There is no single imaging study that serves as the universal reference standard for all aspects of sarcoidosis.

Instead:

Chest radiography is typically the first imaging examination.
High-resolution CT provides detailed structural evaluation of thoracic disease.
FDG PET/CT assesses inflammatory activity throughout the body.
Cardiac MRI is preferred for myocardial fibrosis.
Histopathology remains the diagnostic gold standard.

Each modality contributes complementary information.

7. Can sarcoidosis resolve spontaneously?

Yes.

Many patients, particularly those with limited thoracic disease, experience spontaneous remission without requiring systemic therapy.

However, persistent active inflammation involving the heart, central nervous system, or multiple organs often necessitates prolonged immunosuppressive treatment and careful imaging follow-up.

Clinical Pearls

Pearl 1

Symmetric bilateral hilar lymphadenopathy should always prompt consideration of sarcoidosis, especially when accompanied by systemic constitutional symptoms.

Pearl 2

The Panda Sign and Lambda Sign remain classic Gallium scintigraphic patterns that every radiologist should recognize despite the widespread adoption of FDG PET/CT.

Pearl 3

FDG PET/CT evaluates biological activity, making it invaluable for distinguishing active granulomatous inflammation from chronic fibrotic disease.

Pearl 4

Whole-body PET frequently identifies clinically silent extrapulmonary disease that changes patient staging, biopsy strategy, and treatment planning.

Pearl 5

Imaging findings should always be interpreted in conjunction with histopathology because non-caseating granulomas remain the cornerstone of diagnosis.

Key Takeaways

Sarcoidosis is a multisystem granulomatous disease with highly variable clinical presentations.
Chest radiography and HRCT evaluate structural thoracic abnormalities, whereas FDG PET/CT reveals active inflammatory metabolism.
Gallium scintigraphy introduced the classic Panda Sign and Lambda Sign, which remain important educational imaging signs.
PET/CT plays a pivotal role in biopsy guidance, disease staging, treatment monitoring, and prognostic assessment.
Future advances in molecular imaging, PET/MRI, radiomics, and artificial intelligence are expected to further refine precision imaging and personalized patient management.

References

Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. Journal of Nuclear Medicine. 1994.
Statement on Sarcoidosis. American Thoracic Society (ATS), European Respiratory Society (ERS), World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG).
Judson MA. The Clinical Features of Sarcoidosis: A Comprehensive Review. Clinical Reviews in Allergy & Immunology.
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet.
Mostard RLM, et al. The role of FDG PET/CT in assessing inflammatory activity in sarcoidosis.
Teirstein AS, et al. Imaging of sarcoidosis: Current concepts in diagnosis and management.
Nuclear imaging review articles on FDG PET/CT in sarcoidosis and molecular imaging of granulomatous diseases.